IOL Chemicals and Pharmaceuticals Ltd
NSE:IOLCP
IOL Chemicals and Pharmaceuticals Ltd
IOL Chemicals & Pharmaceuticals Ltd. engages in the manufacture of organic and inorganic chemical compounds. The company is headquartered in Ludhiana, Punjab and currently employs 2,316 full-time employees. The company went IPO on 2010-11-05. The firm is engaged in manufacturing and selling of organic chemicals, specialty, intermediates, and bulk drugs. Its product portfolio covers various therapeutic categories, such as Pain Management, Anti-diabetic, Anti-hypertensive, and Anti-convulsant, amongst others. Its active pharma ingredients (API) product portfolio include Ibuprofen, Ibuprofen Lysinate, Ibuprofen Sodium, Dex-Ibuprofen, Metformin HCL, Clopidogrel Bisulphate (Form II), Pantoprazole Sodium, Fenofibrate, Gabapentin, Lamotrigine, Ursodeoxycholic Acid, Losartan Potassium and Levetiracetam. Its specialty chemical division include Ethyl Acetate, Iso Butyl Benzene, Acetyl Chloride and Mono Chloro Acetic Acid. The firm caters to the pharmaceutical and specialty chemical requirements across both domestic and international markets. The company serves Austria, Belgium, Hungry, Spain, Germany, Italy, Netherlands, Switzerland and others.
IOL Chemicals & Pharmaceuticals Ltd. engages in the manufacture of organic and inorganic chemical compounds. The company is headquartered in Ludhiana, Punjab and currently employs 2,316 full-time employees. The company went IPO on 2010-11-05. The firm is engaged in manufacturing and selling of organic chemicals, specialty, intermediates, and bulk drugs. Its product portfolio covers various therapeutic categories, such as Pain Management, Anti-diabetic, Anti-hypertensive, and Anti-convulsant, amongst others. Its active pharma ingredients (API) product portfolio include Ibuprofen, Ibuprofen Lysinate, Ibuprofen Sodium, Dex-Ibuprofen, Metformin HCL, Clopidogrel Bisulphate (Form II), Pantoprazole Sodium, Fenofibrate, Gabapentin, Lamotrigine, Ursodeoxycholic Acid, Losartan Potassium and Levetiracetam. Its specialty chemical division include Ethyl Acetate, Iso Butyl Benzene, Acetyl Chloride and Mono Chloro Acetic Acid. The firm caters to the pharmaceutical and specialty chemical requirements across both domestic and international markets. The company serves Austria, Belgium, Hungry, Spain, Germany, Italy, Netherlands, Switzerland and others.
Revenue Growth: IOL Chemicals reported Q2 revenue of INR 567.5 crores, up 7.9% year-on-year, driven by volume recovery and a stable product mix.
Margin Expansion: EBITDA grew by 33.3% to INR 64 crores, with margins increasing by 212 bps to 11.1%, supported by cost efficiencies and operating leverage.
Profit Surge: Profit after tax rose 56.7% year-on-year to INR 30 crores, despite a temporary sequential dip due to higher fuel costs from floods.
Guidance Maintained: Management reaffirmed expectations for full-year revenue growth of 10–12% and an EBITDA margin of 13–14% in H2 FY'26.
API Diversification: Non-Ibuprofen APIs are gaining traction, with the paracetamol facility ramping up to 55% capacity and expected to reach 65% by year-end.
Export Focus: The company is increasing its focus on regulated markets, with strategic CapEx and regulatory filings to support export growth.
Temporary Cost Headwind: Fuel and power costs rose by INR 7–8 crores in Q2 but are expected to normalize in Q3 and Q4.
Stable Pricing: Prices for Ibuprofen and Paracetamol remain largely stable; Metformin saw a slight dip due to lower raw material costs.
